Published in Vaccine Weekly, January 16th, 2002
In this 13 patient pilot trial, 5G1.1 appeared to be well tolerated and to be associated with an improvement in skin rash. Dermatomyositis is a connective tissue disease associated with both skin and muscle inflammation resulting in severe skin rash and muscle weakness. Alexion has previously received orphan drug status for 5G1.1 in this disease setting.
"This exploratory pilot trial fulfilled our expectations of identifying a positive signal of 5G1.1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.